Innovative Company Showcase – The Secret Behind Medivir’s Successful Business

By Valerie Lim / 27 September 2011 / 0 comments

Talking about Medivir’s Strategy to become a profitable research-based specialty pharmaceutical company alongside creating value for the company, shareholders and patients, Mr Johan Inborr also introduced the key innovation and commercialization of Medivir at BioPharma Asia Convention 2011. One significant innovation is having a strong pipeline of innovative infectious disease drugs in development with leading pharma partners.

As the Head of Business Development at Medivir Pharma (commercial unit) since August 2009, Mr Inborr is responsible for in-and-out- licensing of marketed or near-market products. He is also actively involved in Medivir’s M&A activities. Before joining Medivir, Johan has held several commercial executive positions of Life Science companies in Swenden, UK and Germany,including CEO of AstaCarotene, VP Business Developmentof Carmeda and Innoventus and VP Marketing and Sales of Vironova.

Here are the main aspects of innovation that has brought Medivir to where it is today:

TMC435 – the leading next generation protease inhibitor
Xerclear® – an exciting commercial opportunity
Strong pipeline in development

For more information about the presentation by Mr Johan Inborr, Medivir, Sweden, get a copy of his slides here!

Join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!